Hansa Pink Sheet Today

HNSBF Stock  USD 5.20  0.72  12.16%   
Market Performance
3 of 100
Odds Of Distress
Over 51
Hansa Biopharma is trading at 5.20 as of the 4th of February 2023, a -12.16 percent decrease since the beginning of the trading day. The stock's lowest day price was 5.2. Hansa Biopharma has 51 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Hansa Biopharma AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of February 2021 and ending today, the 4th of February 2023. Click here to learn more.
Fiscal Year End
Hansa Biopharma AB , a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G -mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. Hansa Biopharma AB was incorporated in 2007 and is headquartered in Lund, Sweden. The company has 52.44 M outstanding shares. More on Hansa Biopharma AB
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Hansa Biopharma Pink Sheet Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hansa Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hansa Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEOGoran Arvidson
Macroaxis Advice
The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Hansa Biopharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Hansa Biopharma AB [HNSBF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Small-Cap' category with a current market capitalization of 277.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hansa Biopharma's market, we take the total number of its shares issued and multiply it by Hansa Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hansa Biopharma AB classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 52.44 M outstanding shares. Hansa Biopharma AB has accumulated about 60.15 M in cash with (481.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58.
Check Hansa Biopharma Probability Of Bankruptcy
Hansa Biopharma secures a total of 52.44 Million outstanding shares. 30% of Hansa Biopharma AB outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation

Check Hansa Ownership Details

Hansa Stock Price Odds Analysis

What are Hansa Biopharma's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Hansa Biopharma jumping above the current price in 90 days from now is about 48.73%. The Hansa Biopharma AB probability density function shows the probability of Hansa Biopharma pink sheet to fall within a particular range of prices over 90 days. Assuming the 90 days horizon the pink sheet has a beta coefficient of 1.1096. This usually indicates Hansa Biopharma AB market returns are highly-sensitive to returns on the market. As the market goes up or down, Hansa Biopharma is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Hansa Biopharma AB is significantly underperforming NYSE Composite.
  Odds Below 5.2HorizonTargetOdds Above 5.2
51.14%90 days
Based on a normal probability distribution, the odds of Hansa Biopharma to move above the current price in 90 days from now is about 48.73 (This Hansa Biopharma AB probability density function shows the probability of Hansa Pink Sheet to fall within a particular range of prices over 90 days) .

Hansa Biopharma AB Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Hansa Biopharma market risk premium is the additional return an investor will receive from holding Hansa Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Hansa Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Hansa Biopharma's alpha and beta are two of the key measurements used to evaluate Hansa Biopharma's performance over the market, the standard measures of volatility play an important role as well.

Hansa Stock Against Markets

Picking the right benchmark for Hansa Biopharma pink sheet is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Hansa Biopharma pink sheet price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Hansa Biopharma is critical whether you are bullish or bearish towards Hansa Biopharma AB at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Hansa Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Analysis Now


Bond Analysis

Evaluate and analyze corporate bonds as a potential investment for your portfolios.
All  Next Launch Module

Hansa Biopharma Corporate Directors

Hansa Biopharma corporate directors refer to members of a Hansa Biopharma board of directors. The board of directors generally takes responsibility for the Hansa Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Hansa Biopharma's board members must vote for the resolution. The Hansa Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Mats Blom - DirectorProfile
Angelica Loskog - DirectorProfile
Cindy Wong - Independent DirectorProfile
Hans Schikan - DirectorProfile

Invested in Hansa Biopharma AB?

The danger of trading Hansa Biopharma AB is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Hansa Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Hansa Biopharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Hansa Biopharma AB is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please check Risk vs Return Analysis. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Hansa Pink Sheet analysis

When running Hansa Biopharma AB price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Please note, there is a significant difference between Hansa Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Hansa Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hansa Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.